| P2093 | author name string | James H Finke | |
| | Yana G Najjar | |
| P2860 | cites work | Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells | Q24658240 |
| | Myeloid-derived suppressor cells as regulators of the immune system | Q28131637 |
| | Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma | Q28247085 |
| | Vaccination of Metastatic Renal Cancer Patients with MVA-5T4: A Randomized, Double-Blind, Placebo-Controlled Phase III Study | Q28294419 |
| | Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice | Q28385532 |
| | Coordinated regulation of myeloid cells by tumours | Q28395157 |
| | Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function | Q28510096 |
| | Subsets of myeloid-derived suppressor cells in tumor-bearing mice | Q29614297 |
| | A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells | Q33335471 |
| | Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells | Q33567728 |
| | Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine | Q33584867 |
| | Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer. | Q33733198 |
| | Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells | Q33919954 |
| | Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination | Q33932627 |
| | Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes | Q33978763 |
| | Targeting immune suppressing myeloid-derived suppressor cells in oncology. | Q34082067 |
| | Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects. | Q34473451 |
| | COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells | Q34784887 |
| | Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination | Q35033957 |
| | All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients | Q35062106 |
| | The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies | Q35207756 |
| | Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. | Q35222367 |
| | Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model | Q35345202 |
| | Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy | Q35597086 |
| | Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice | Q35648172 |
| | Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy | Q36108095 |
| | Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained | Q36186882 |
| | Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression | Q36259867 |
| | Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer | Q36260673 |
| | Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma | Q36403544 |
| | Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity | Q36996588 |
| | A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. | Q37006834 |
| | Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells | Q37147482 |
| | PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment | Q37193568 |
| | A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. | Q37418671 |
| | Therapeutic targeting of myeloid-derived suppressor cells | Q37555487 |
| | Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients | Q37961577 |
| | Myeloid-derived suppressor cells in cancer patients: a clinical perspective. | Q37981536 |
| | Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells | Q38296397 |
| | Response to sunitinib in combination with proton beam radiation in a patient with chondrosarcoma: a case report. | Q39252570 |
| | The addition of Sunitinib to radiation delays tumor growth in a murine model of glioblastoma | Q39636415 |
| | 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity | Q39715226 |
| | Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity | Q40013431 |
| | A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model | Q40099109 |
| | Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression | Q40338318 |
| | Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity | Q40372686 |
| | Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. | Q40474320 |
| | Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma | Q41773542 |
| | Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer | Q42183073 |
| | Neutrophil degranulation and immunosuppression in patients with GBM: restoration of cellular immune function by targeting arginase I. | Q43487731 |
| | Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells | Q43582877 |
| | Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. | Q43640348 |
| | Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma | Q43843476 |
| | Phase 1B study to improve immune responses in head and neck cancer patients using escalating doses of 25-hydroxyvitamin D3. | Q44675420 |
| | Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival | Q44925875 |
| | Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice | Q44946383 |
| | Myeloid-derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties | Q46064310 |
| | Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients | Q46093084 |
| | Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients | Q46312545 |
| | Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion | Q46440292 |
| | Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma. | Q46529900 |
| | Overcoming immunosuppression in the melanoma microenvironment induced by chronic inflammation | Q46897065 |
| | IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. | Q47883923 |
| | Complete pathological response after sequential therapy with sunitinib and radiotherapy for metastatic clear cell renal carcinoma. | Q51364449 |
| | Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival | Q56986695 |
| | Identification of a New Subset of Myeloid Suppressor Cells in Peripheral Blood of Melanoma Patients With Modulation by a Granulocyte-Macrophage Colony-Stimulation Factor–Based Antitumor Vaccine | Q60311223 |
| | Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells | Q80274418 |
| | Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response | Q80582229 |
| | CD11b+/Gr-1+ immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1beta-secreting cells | Q81598364 |
| | Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign | Q84256128 |
| P304 | page(s) | 49 | |
| P577 | publication date | 2013-03-15 | |
| P1433 | published in | Frontiers in Oncology | Q26839986 |
| P1476 | title | Clinical perspectives on targeting of myeloid derived suppressor cells in the treatment of cancer | |
| P478 | volume | 3 | |